Travere Therapeutics, Inc. (TVTX)
NASDAQ
Healthcare
Biotechnology
$42.97
▼ -4.60%
Market Cap
$4.00B
Sector
Healthcare
Industry
Biotechnology
Beta
1.14
52-Wk Range
13.88-48.61
CEO
Eric Dube
Country
US
Currency
USD
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment…
Open full interactive analysis & DCF →